
CLAIMS

What is claimed is:

1. Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein the medicament is to be orally administered for at least 116 weeks, and wherein the subject has been previously treated with an erythropoiesis stimulating agent (ESA) within six or eight weeks prior to or during a screening period before the medicament is to be administered.

2. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein hemoglobin levels are increased to 10.0 – 13.0 g/dL from a baseline hemoglobin level in the subject.

3. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein hemoglobin levels are maintained or controlled at 10.0 – 13.0 g/dL.

4. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 128 weeks.

5. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 140 weeks.

6. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 156 weeks.

7. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 168 weeks.

8. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 180 weeks.

9. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 192 weeks.

10. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 208 weeks.

11. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least 260 weeks.

12. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-11, wherein the subject has non-dialysis dependent chronic kidney disease (NDD-CKD).

13. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-11, wherein the subject has dialysis-dependent chronic kidney disease (DD-CKD).

14. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-13, wherein the screening period is up to eight weeks.

15. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-13, wherein the screening period is up to 6 weeks.

16. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-13, wherein the screening period is up to 4 weeks.

17. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-16, wherein the erythropoiesis stimulating agent is epoetin, darbepoetin alfa (DA), or methoxy polyethylene glycol-epoetin beta (epoetin beta pegol).

18. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the epoetin is epoetin alfa, epoetin beta, epoetin gamma, epoetin kappa, or a combination thereof.

19. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 18, wherein the subject has been previously treated with epoetin alfa in an amount of 10 U/kg to 500 U/kg 3 times weekly.

20. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with epoetin beta pegol in a dosage amount of 0.6 mcg/kg to 1.20 mcg/kg once every two weeks.

21. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with epoetin beta pegol in a dosage amount of 0.6 mcg/kg to 1.20 mcg/kg once monthly.

22. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with epoetin at a dose of ≥ 4500 IU weekly.

23. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with epoetin at a dose of about <4500 IU.

24. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of 0.45 mcg/kg to 0.75 mcg/kg once every four weeks.

25. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of 0.45 mcg/kg to 0.75 mcg/kg once every two weeks.

26. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of 0.45 mcg/kg to 0.75 mcg/kg once a week.

27. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with darbepoetin alfa in a dosage amount of ≥ 15 µg weekly.

28. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 17, wherein the subject has been previously treated with darbepoetin alfa in a dosage amount of < 15 µg weekly.

29. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-28, wherein the medicament is to be administered at a dosage comprising 150-600 mg.

30. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-29, wherein the medicament is to be administered at a dosage comprising 150 mg.

31. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-29, wherein the medicament is to be administered at a dosage comprising 300 mg.

32. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-29, wherein the medicament is to be administered at a dosage comprising 450 mg.

33. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-29, wherein the medicament is to be administered at a dosage comprising 600 mg.

34. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-33, wherein the medicament is to be administered once daily.

35. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-33, wherein the medicament is to be administered once a week.

36. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-33, wherein the medicament is to be administered three times a week.

37. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-36, wherein the subject has a baseline hemoglobin level of <10 g/dL.

38. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the hemoglobin levels are increased to 10.0-11.0 g/dL.

39. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the hemoglobin levels are increased to 11.0-13.0 g/dL.

40. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 29-33, wherein the medicament is to be administered comprising adjusting the dosage by about 150 mg if the subject's hemoglobin (Hb) level is < 10.0 g/dL or > 11.5 g/dL.

41. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 40, wherein the medicament is to be administered further comprising increasing the dosage, and the subject's hemoglobin (Hb) level is < 10.0 g/dL.

42. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 40, wherein the medicament is to be administered further decreasing the dosage.

43. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 29-33, and 40, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 2 weeks.

44. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 29-33, and 40-42, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 4 weeks.

45. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 29-33, and 40-42, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 6 weeks.

46. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 29-33, wherein the medicament is to be administered further comprising decreasing the dose no more than once in at least every 2 weeks.

47. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-37, wherein the hemoglobin levels are maintained or controlled at 10.0 – 12.0 g/dL.

48. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-37, wherein the hemoglobin levels are maintained or controlled at 11.0 – 13.0 g/dL.

49. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the patient has a serum ferritin level of ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.

50. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 49, wherein the patient has a decrease in serum ferritin level relative to a baseline level.

51. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-50, wherein the patient is ≥ 18 years old.